A Prospective, Mono-Country and Multi-center Study to Observe Safety and Effectiveness of Adalimumab in KoREan Intestinal Behcet's Disease(BD) Patients (AMORE)

AbbVie

Status: Completed

Conditions: Intestinal Behcet's Disease (BD)

Study type: Observational

Funder types: Industry

Identifiers

NCT02687828

P15-760

Details and patient eligibility

About

This study evaluates the safety profile and effectiveness of adalimumab in Korean intestinal Behcet's disease (BD) patients in routine clinical practice.

Enrollment: 59 patients

Sex: All

Ages: 19 to 99 years old

Volunteers: No Healthy Volunteers

Inclusion criteria

• Subjects must be an adult >= 19 years
• Subjects who are eligible to be treated with adalimumab for intestinal Behcet's disease in accordance with the approved label in Korea
• Subjects provide written authorization form for use/disclose of personal health data prior to participating in this study

Exclusion criteria

• Subjects who are contraindicated to any anti-TNF agent
• Female subjects who are pregnant or breast feeding
• Subjects who are participating in other interventional clinical trials

Trial design

59 participants in 1 patient group

Subjects receiving adalimumab

Description:

The subjects who are prescribed adalimumab for intestinal Behcet's disease (BD) in accordance with the approved Korean label.